Alla studier
Aktiv men inte rekryterandeFAS1, FAS2INTERVENTIONELL

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

This research study is looking into a new treatment called brenetafusp (sometimes called IMC-F106C) for people with specific types of advanced solid cancers. These are cancers that require a special marker called PRAME to be present, and patients also need a particular inherited tissue type called HLA-A2. The study aims to find out the safest and most effective dose of brenetafusp. It will be given either on its own or in combination with other existing cancer treatments, such as chemotherapy, immunotherapy, or other targeted drugs. By doing this, researchers hope to understand if brenetafusp can help control the cancer and improve patient well-being, especially for those whose previous treatments haven't worked.

Överblick

Status
Aktiv men inte rekryterande
Fas
FAS1, FAS2
Sponsor
Immunocore Ltd
Inskrivningsmål
410
Starta
25 Feb 2020
Beräknad slutförande
01 dec 2027

Vad handlar denna studie om?

This research study is about a new potential cancer medicine called brenetafusp (also known as IMC-F106C). It's designed to help your body's own immune system fight cancer. Brenetafusp works by targeting a specific protein called PRAME, which is found on the surface of some cancer cells. For this treatment to work, your cancer needs to have this PRAME protein, and you also need a particular gene marker called HLA-A2 in your body.

The study is split into two main parts. The first part aims to find the right and safest dose of brenetafusp. Researchers will test it alone and in combination with other well-known cancer treatments, like chemotherapy, other immune-boosting drugs, or targeted therapies. This is to see how well these combinations are tolerated and what dose is best to move forward with. In the second part, once the best dose is found, the study will focus on how well brenetafusp works to treat specific advanced solid cancers.

This is a "first-in-human" trial, meaning it's one of the first times this drug is being tested in people. The goal is to see if brenetafusp can be a useful new option for adults with advanced solid cancers that have either returned, not responded to standard treatments, or if the patient can't tolerate those standard treatments. The study aims to make sure the treatment is safe and to see how effective it is in shrinking or controlling the cancer.

Viktiga punkter

  • This study is testing a new cancer medicine, brenetafusp, for specific advanced solid cancers.
  • Brenetafusp works with your immune system to target cancer cells with the PRAME protein.
  • You need to have a specific genetic marker (HLA-A2) for this treatment.
  • It aims to find the safest dose and see how well it works, both alone and with other treatments.
  • Participation involves regular check-ups, and side effects are closely monitored.
  • This is an opportunity for those whose current treatments are no longer effective or tolerated.

Vem kan vara berättigad?

To join this study, you need to be an adult with a type of advanced solid cancer that has either returned, not fully responded to previous treatments, or if you couldn't tolerate those treatments. Your cancer must have a specific marker called PRAME, and you must also have a genetic marker called HLA-A*02:01. You should generally be fit and able to carry out your daily activities.

There are several reasons why you might not be able to join. For example, if you have cancer that has spread to your brain and is causing symptoms, or if you've recently had problems with your bowel. Serious or ongoing infections like Hepatitis B, Hepatitis C, or HIV would also mean you can't take part. If you have any serious heart, lung, or immune system conditions, or if you're currently pregnant or breastfeeding, this study would not be suitable for you.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Är du vuxen (18 år eller äldre)?
  2. Do you have an advanced solid cancer that has progressed or not responded to other treatments?
  3. Do you know if your cancer has the PRAME marker?
  4. Do you know if you have the HLA-A*02:01 genetic marker?
  5. Are you generally feeling well and able to manage daily activities?
  6. Are you able and willing to use effective contraception if needed?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you join this study, you will receive brenetafusp, potentially alongside other cancer medicines. You'll have regular visits to the clinic for medical check-ups, blood tests, and scans to monitor your health and how the treatment is working. Depending on the phase of the study and the combination of treatments being used, these visits might be weekly or every few weeks. Doctors will closely watch for any side effects. The total length of your participation will depend on how you respond to the treatment and the study's design for your specific situation. You might also need to use effective contraception if you are able to become pregnant.

Potentiella risker och fördelar

Participating in a clinical trial offers the chance to try a new treatment that might help your cancer when standard options haven't worked or aren't suitable. While there's no guarantee the treatment will work for you, your health will be closely monitored, and you'll receive dedicated medical care. However, new drugs can have side effects that aren't fully known yet, and some could be serious. There's also the chance the treatment might not help your cancer. Remember, joining is completely voluntary, and you can withdraw from the study at any time without affecting your medical care.

Locations (76)

  • University of California - San Diego
    Verifierat postnummer
    La Jolla, USA
  • Angeles Clinic and Research Institute
    Verifierat postnummer
    Los Angeles, USA
  • University of California Davis Comprehensive Center
    Verifierat postnummer
    Sacramento, USA
  • University of Colorado
    Verifierat postnummer
    Aurora, USA
  • Georgetown University Medical Center
    Verifierat postnummer
    Washington D.C., USA
  • Houston Lee Moffitt Cancer Center & Research Institute
    Verifierat postnummer
    Tampa, USA
  • The University of Chicago Medical Center
    Verifierat postnummer
    Chicago, USA
  • University of Iowa
    Verifierat postnummer
    Iowa City, USA
  • Massachusetts General Hospital
    Verifierat postnummer
    Boston, USA
  • John Theurer Cancer Center at Hackensack University Medical Center
    Verifierat postnummer
    Hackensack, USA
  • Columbia University Medical Center
    Verifierat postnummer
    New York, USA
  • Memorial Sloan Kettering
    Verifierat postnummer
    New York, USA

Vanliga frågor

What is PRAME?

PRAME is a specific protein found on some cancer cells that this new medicine is designed to target.

What does HLA-A2 mean?

HLA-A2 is a specific genetic marker that your body needs to have for this immune treatment to work effectively.

Will I get brenetafusp alone or with other drugs?

That depends on which part of the study you join. It might be given by itself or combined with other common cancer treatments.

What if my cancer has spread to my brain?

If your cancer has spread to your brain and is causing symptoms, this study may not be suitable for you.

Hur länge kommer jag att vara med i studien?

The length of time you're in the study will vary, depending on how you respond to the treatment and the specific study plan.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.